Abstract
Erectile Dysfunction (ED) is one of the most common conditions affecting middle-aged and older men. Over the past few decades, oral phosphodiesterase type 5 inhibitors have been used to treat ED. However, these oral medications require on-demand access and are not effective in some hard-totreat populations. Moreover, there are no effective alternative treatments for ED. Based on results from preclinical models designed to provide long-term improvement of ED and other related conditions, gene therapy has shown great potential as a novel therapy for clinical management of ED. Gene therapy refers to the use of viral and non-viral vectors to deliver therapeutic genes to tissues via direct or transduced cell-mediated approaches. With the growing knowledge on the molecular mechanisms involved in the pathophysiology of ED, a number of therapeutic gene strategies have been extensively tested and proven to be effective in many animal models. However, only a few of them have been evaluated in clinical trials. This is due to safety concerns that need to be addressed before the clinical application can be considered. In this review, we summarize the key advancements in gene therapy for ED treatment, with an emphasis on the emerging stem cell-based approaches as well as other combinational strategies. The challenges facing the clinical application of gene therapy for ED treatment are also discussed.
Keywords: Erectile dysfunction, gene therapy, cell-based therapy, stem cells, gene delivery, erection.
Current Gene Therapy
Title:Advances in Gene Therapy for Erectile Dysfunction: Promises and Challenges
Volume: 18 Issue: 6
Author(s): Botao Yu, Changjing Wu, Tao Li, Feng Qin and Jiuhong Yuan*
Affiliation:
- Andrology Laboratory, West China Hospital, Sichuan University, Chengdu 610041,China
Keywords: Erectile dysfunction, gene therapy, cell-based therapy, stem cells, gene delivery, erection.
Abstract: Erectile Dysfunction (ED) is one of the most common conditions affecting middle-aged and older men. Over the past few decades, oral phosphodiesterase type 5 inhibitors have been used to treat ED. However, these oral medications require on-demand access and are not effective in some hard-totreat populations. Moreover, there are no effective alternative treatments for ED. Based on results from preclinical models designed to provide long-term improvement of ED and other related conditions, gene therapy has shown great potential as a novel therapy for clinical management of ED. Gene therapy refers to the use of viral and non-viral vectors to deliver therapeutic genes to tissues via direct or transduced cell-mediated approaches. With the growing knowledge on the molecular mechanisms involved in the pathophysiology of ED, a number of therapeutic gene strategies have been extensively tested and proven to be effective in many animal models. However, only a few of them have been evaluated in clinical trials. This is due to safety concerns that need to be addressed before the clinical application can be considered. In this review, we summarize the key advancements in gene therapy for ED treatment, with an emphasis on the emerging stem cell-based approaches as well as other combinational strategies. The challenges facing the clinical application of gene therapy for ED treatment are also discussed.
Export Options
About this article
Cite this article as:
Yu Botao , Wu Changjing , Li Tao , Qin Feng and Yuan Jiuhong *, Advances in Gene Therapy for Erectile Dysfunction: Promises and Challenges, Current Gene Therapy 2018; 18 (6) . https://dx.doi.org/10.2174/1566523218666181004145424
DOI https://dx.doi.org/10.2174/1566523218666181004145424 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Melatonin Signaling in Health and Disease
Melatonin regulates a multitude of physiological functions, including circadian rhythms, acting as a scavenger of free radicals, an anti-inflammatory agent, a modulator of mitochondrial homeostasis, an antioxidant, and an enhancer of nitric oxide bioavailability. AANAT is the rate-limiting enzyme responsible for converting serotonin to NAS, which is further converted to ...read more
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers.
Programmed cell death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
The now and future of gene transfer technologies
Gene and cell therapies rely on a gene delivery system which is safe and effective. Both viral and non-viral vector systems are available with specific pros and cons. The choice of a vector system is largely dependent on the application which is a balance between target tissue/disease and safety, efficacy ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Association Between Biofilm Formation Gene Bla <i>exoU</i> and Metallo and
Extend Spectrum Beta-lactamase Production of Multidrug Resistance
<i>Pseudomonas aeruginosa</i> in Clinical Samples
Combinatorial Chemistry & High Throughput Screening Cardiac Adiposity and Cardiovascular Risk: Potential Role of Epicardial Adipose Tissue
Current Cardiology Reviews Modulation of Ischemic Brain Injury and Neuroinflammation by Adenosine A2A Receptors
Current Pharmaceutical Design Translational Application of In Vivo Imaging and Analysis of Atherosclerotic Plaque Vulnerability Assessment
Recent Patents on Medical Imaging Far-infrared Ray-mediated Antioxidant Potentials are Important for Attenuating Psychotoxic Disorders
Current Neuropharmacology Arterial Stiffness and Cardiovascular Drugs
Current Pharmaceutical Design Nuclear Targeting of Gold Nanoparticles for Improved Therapeutics
Current Topics in Medicinal Chemistry Prophylactic Neuroprotection
Current Drug Targets Use of High-intensity Focused Ultrasound in the Management of Extra-abdominal Desmoid Tumors
Current Medical Imaging Treatment of HCV-Related Mixed Cryoglobulinemia
Current Drug Targets Effect on Morphology, Osmotic Fragility and Electro Kinetic Potential of Erythrocytes in Hypertension
Current Hypertension Reviews Challenges and Perspectives of Antiplatelet Therapy in Patients with Diabetes Mellitus and Coronary Artery Disease
Current Pharmaceutical Design Stem Cells: Clinical Trials Results The End of the Beginning or the Beginning of the End?
Cardiovascular & Hematological Disorders-Drug Targets Soluble Epoxide Hydrolase, a Target with Multiple Opportunities for Cardiovascular Drug Discovery
Current Topics in Medicinal Chemistry Subject Index To Volume 5
CNS & Neurological Disorders - Drug Targets Beta-Caryophyllene Suppresses Ovarian Cancer Proliferation by Inducing Cell Cycle Arrest and Apoptosis
Anti-Cancer Agents in Medicinal Chemistry HPMC- A Marvel Polymer for Pharmaceutical Industry-Patent Review
Recent Advances in Drug Delivery and Formulation Targeting T-Cell Adhesion Molecules for Drug Design
Current Pharmaceutical Design Flow Cytometric Analysis of Pro-inflammatory Cytokine Production in Hyperglycemic Mouse Model
Recent Patents on Food, Nutrition & Agriculture Resistin and Oxidative Stress as Markers of Atherosclerosis in Obstructive Sleep Apnea
Current Respiratory Medicine Reviews